Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept and TWEAK in Psoriatic and Rheumatoid Arthritis
NCT02164214Phase 3Completed
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Sep 2011
- Primary completion
- Mar 2015
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, open-label trial of etanercept in psoriatic arthritis (PsA) and rheumatoid arthritis (RA) (2 arms), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: serum levels of soluble TWEAK at 42 months. Started Sep 2011; status: completed.
02
Drugs
etanercept
03
Conditions
psoriatic arthritis (PsA)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02164214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02164214.